武汉大学人民医院湖北省人民医院

院内导航

江应安传染
感染性疾病科主任，教授，一级主任医师，博士生导师

A+ A-

导师介绍

姓名	江应安
出生年月	1965年10月
单位	武汉大学人民医院感染性疾病科
所属学科	临床医学-内科学
职务、职称及头衔	武汉大学人民医院感染性疾病科主任，教授，一级主任医师，博士生导师
E-mail	jiangya_cn@aliyun.com
联系方式	13720389866
研究方向	干细胞治疗肝硬化的基础和临床研究
个人简介	干细胞治疗传染性疾病的临床研究，主持国家重点研发计划子课题1项、国家干细胞临床研究备案项目2项、国家自然科学基金面上项目1项、武汉大学教育发展基金会抗衰老基金项目负责人，湖北省自然科学基金、湖北省卫生健康委项目等省级项目6项，以第一作者或通讯作者发表学术论文80余篇，主要发表在Oncogene,Clinical translational Medicine, GUT、Stem Cell Research & Therapy、J Clin Transl Hepatol、Frontier in immunology、Biomaterials Science、liver international、msphere、Eur J Pharmacol、中华临床感染病杂志、中华传染病杂志、中华实验外科杂志、中华消化杂志、中华消化外科杂志等本领域国内外知名期刊，研究成果获湖北省科技进步三等奖2项，主编专著《胃癌新探》、副主编专著《重型肝炎新论》，入选第六批武昌名师工作室负责人。已培养硕士生12名，博士生3名。目前正在培养的博士生3名，硕士生3名。
学术任职与荣誉	中华医学会肝病学分会第七、八届委员会委员湖北省医学会肝病学分会第五届委员会副主任委员武汉市医学会第十七届理事会副会长《中华临床感染病杂志》编委《中华肝脏病杂志》编委《临床肝胆病杂志》第十五届编委
教育履历	1988.09-1991.06武汉大学第一临床学院传染病学硕士研究生获硕士学位 2000.09-2003.06武汉大学第一临床学院内科学博士研究生获博士学位
工作履历	1991.06-1993.11湖北医学院附属第一医院传染科住院医师 1993.11-1996.02湖北医学院附属第一医院传染科主治医师 1996.02-1999.03湖北医科大学附属第一医院医务科副科长、副主任医师、副教授 1999.03-2000.10湖北医科大学附属第一医院医疗部副部长 2000.10-2008.06黄石市中心医院院长、党委书记（其间：2000.09-2003.06武汉大学医学部在职博士研究生；2003.04主任医师） 2008.06-2008.09武汉大学人民医院教授，博士生导师 2008.09-2010.07武汉大学人民医院医疗部部长兼感染管理办公室主任 2010.07-2011.06武汉大学人民医院院长助理 2011.06-2012.12武汉大学人民医院汉川医院院长 2012.12-2021.12武汉大学人民医院党委常委、副院长2021.12-至今武汉大学人民医院教授：2023.06- 兼感染性疾病科科主任）
成果获奖	1.食管曲张静脉套扎与门脉高压性胃病，湖北省人民政府科技进步奖叁等奖，2004J-240-3-140-120-R02 2、食管癌支架植入术后再狭窄的临床及病理研究，湖北省人民政府科技进步奖叁等奖，2005J-209-3-115-023-R07
代表性论著	1. Yao L, Hu X, Dai K, Yuan M, Liu P, Zhang Q, Jiang Y. Mesenchymal stromal cells: promising treatment for liver cirrhosis. Stem Cell Res Ther. 2022 Jul 15;13(1):308. 2. Yuan M, Hu X, Yao L, Jiang Y, Li L. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. Stem Cell Res Ther. 2022 May 3;13(1):179. 3. Yao L, Hu X, Yuan M, Zhang Q, Liu P, Yang L, Dai K, Jiang Y. IGF2-NR4A2 Signaling Regulates Macrophage Subtypes to Attenuate Liver Cirrhosis. J Clin Transl Hepatol. 2023 Aug 28;11(4):787-799. 4. Liu P, Yao L, Hu X, Wang Z, Xiong Z, Jiang Y. Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases. J Gastroenterol Hepatol. 2023 Jun 4. 5. Yuan M, Hu X, Yao L, Liu P, Jiang Y, Li L. Comprehensive bioinformatics and machine learning analysis identify VCAN as a novel biomarker of hepatitis B virus-related liver fibrosis. Front Mol Biosci. 2022 Oct 7;9:1010160. 6. Zeng Z, Zhang X, Jiang CQ, Zhang YG, Wu X, Li J, Tang S, Li L, Gu LJ, Xie XY, Jiang YA. Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening. Oncogene. 2022 Apr;41(14):2069-2078. 7. Yuan M, Yao L, Hu X, Jiang Y, Li L. Identification of effective diagnostic biomarker and immune cell infiltration characteristics in acute liver failure by integrating bioinformatics analysis and machine-learning strategies. Front Genet. 2022 Sep 28;13:1004912. 8. Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, Ye P, Li H, Yu L, Zhou X, Zhou C, Chen X, Zheng X, Xu K, Cai H, Zheng S, Jiang W, Wu X, Li D, Chen L, Luo Q, Wang Y, Qu J, Li Y, Zheng W, Jiang Y, Tang L, Xiang C, Li L. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021 Feb;11(2):e297. 9. Hu X, Jiao F, Zhang L, Jiang Y. Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway. Front Pharmacol. 2021 Apr 29;12:654986. 10. Han H, Yi J, Cheng G, Jiang W, Brożek GM, Jiang Y, Zhu C, Xia Y. SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020. mSphere. 2021 Apr 21;6(2):e01062-20. 11. Meng Y, Zhang T, Zheng R, Ding S, Yang J, Liu R, Jiang Y, Jiang W. Depletion of Demethylase KDM6 Enhances Early Neuroectoderm Commitment of Human PSCs. Front Cell Dev Biol. 2021 Sep 8;9:702462. 12. Chen B, Li F, Zhu XK, Xie W, Hu X, Zan MH, Li X, Li QY, Guo SS, Zhao XZ, Jiang YA, Cao Z, Liu W. Highly biocompatible and recyclable biomimetic nanoparticles for antibiotic-resistant bacteria infection. Biomater Sci. 2021 Feb 9;9(3):826-834. 13. Liu R, Zhao L, Cheng X, Han H, Li C, Li D, Liu A, Gao G, Zhou F, Liu F, Jiang Y, Zhu C, Xia Y. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int. 2021 Apr;41(4):720-730. 14. Han H, Xu Z, Cheng X, Zhong Y, Yuan L, Wang F, Li Y, Liu F, Jiang Y, Zhu C, Xia Y. Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19 Patients. mSphere. 2020 Oct 7;5(5):e00922-20. 15.Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, Ye P, Chen X, Wang B, Xu Z, Zhang Q, Xu X, Gao H, Wu X, Li D, Jiang W, Qu J, Xiang C, Li L. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020 Oct;14(5):664-673. 16. Dai K, Huang Y, Chen Z, Sun X, Yang L, Jiang Y. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model. Eur J Immunol. 2018 Apr;48(4):683-695. 17. Jiang WL, Hu XP, Hu ZP, Tang Z, Wu HB, Chen LH, Wang ZW, Jiang YA. Morbidity and Mortality of Nosocomial Infection after Cardiovascular Surgery: A Report of 1606 Cases. Curr Med Sci. 2018 Apr;38(2):329-335. 18. Dai K, Huang L, Huang YB, Chen ZB, Yang LH, Jiang YA. 1810011o10 Rik Inhibits the Antitumor Effect of Intratumoral CD8+ T Cells through Suppression of Notch2 Pathway in a Murine Hepatocellular Carcinoma Model. Front Immunol. 2017 Mar 22;8:320. 19.戴锴,包安裕,叶鹏,徐铭,张钦然,周宇,江万里,江吴边,王慧敏,朱梦飞,汤灵玲,祝成亮,夏宇尘,江应安,邹秀芬,李兰娟.武汉地区107例重症新型冠状病毒肺炎患者的预后危险因素分析[J].中华临床感染病杂志,2020,13(04):257-263. 20.江万里,王慧敏,叶鹏,邹秀芬,张钦然,周宇,江吴边,褚爱春,戴锴,胡雪,江应安.新型冠状病毒肺炎死亡患者80例的临床特征分析[J].中华传染病杂志,2021,39(01):9-14.

Name	Ying-an Jiang
Date of birth	Oct，1965
Department	Infectious disease, Department, Renmin Hospital,Wuhan University
Title	Director, Professor, Doctoral tutor
Email	jiangya_cn@aliyun.com
TEL	13720389866
Research Direction	Mesenchymal Stem Cells therapy for Liver cirrohosis
Personal Profile	He is mainly engaged in the research of prevention and treatment of chronic liver disease and mesenchymal stem cells therapy for Liver cirrohosis and COVID-19. He has been awarded 2 item for the national stem cell clinical research record project, 1 item for the sub-project of the National Key Research and Development Program, 1 item for the National Natural Science Foundation, and 6 items for the provincial natural science foundation. He is a chief editor of monograph on gastric cancer and an associate editor of monograph on liver disease. Besides, there are more than 80 articles published in domestic and abroad journals in the field. He obtained the 3rd Prize of Hubei province Science & Technology Development twice. By now, he has educated 12 masters and 3 doctors. At present, there are 3 doctors and 3 masters studying with him.
Selected Publications	1. Yao L, Hu X, Dai K, Yuan M, Liu P, Zhang Q, Jiang Y. Mesenchymal stromal cells: promising treatment for liver cirrhosis. Stem Cell Res Ther. 2022 Jul 15;13(1):308. 2. Yuan M, Hu X, Yao L, Jiang Y, Li L. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. Stem Cell Res Ther. 2022 May 3;13(1):179. 3. Yao L, Hu X, Yuan M, Zhang Q, Liu P, Yang L, Dai K, Jiang Y. IGF2-NR4A2 Signaling Regulates Macrophage Subtypes to Attenuate Liver Cirrhosis. J Clin Transl Hepatol. 2023 Aug 28;11(4):787-799. 4. Liu P, Yao L, Hu X, Wang Z, Xiong Z, Jiang Y. Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases. J Gastroenterol Hepatol. 2023 Jun 4. 5. Yuan M, Hu X, Yao L, Liu P, Jiang Y, Li L. Comprehensive bioinformatics and machine learning analysis identify VCAN as a novel biomarker of hepatitis B virus-related liver fibrosis. Front Mol Biosci. 2022 Oct 7;9:1010160. 6. Zeng Z, Zhang X, Jiang CQ, Zhang YG, Wu X, Li J, Tang S, Li L, Gu LJ, Xie XY, Jiang YA. Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening. Oncogene. 2022 Apr;41(14):2069-2078. 7. Yuan M, Yao L, Hu X, Jiang Y, Li L. Identification of effective diagnostic biomarker and immune cell infiltration characteristics in acute liver failure by integrating bioinformatics analysis and machine-learning strategies. Front Genet. 2022 Sep 28;13:1004912. 8. Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, Ye P, Li H, Yu L, Zhou X, Zhou C, Chen X, Zheng X, Xu K, Cai H, Zheng S, Jiang W, Wu X, Li D, Chen L, Luo Q, Wang Y, Qu J, Li Y, Zheng W, Jiang Y, Tang L, Xiang C, Li L. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021 Feb;11(2):e297. 9. Hu X, Jiao F, Zhang L, Jiang Y. Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway. Front Pharmacol. 2021 Apr 29;12:654986. 10. Han H, Yi J, Cheng G, Jiang W, Brożek GM, Jiang Y, Zhu C, Xia Y. SARS-CoV-2 Antibody Seroprevalence in Wuhan, China, from 23 April to 24 May 2020. mSphere. 2021 Apr 21;6(2):e01062-20. 11. Meng Y, Zhang T, Zheng R, Ding S, Yang J, Liu R, Jiang Y, Jiang W. Depletion of Demethylase KDM6 Enhances Early Neuroectoderm Commitment of Human PSCs. Front Cell Dev Biol. 2021 Sep 8;9:702462. 12. Chen B, Li F, Zhu XK, Xie W, Hu X, Zan MH, Li X, Li QY, Guo SS, Zhao XZ, Jiang YA, Cao Z, Liu W. Highly biocompatible and recyclable biomimetic nanoparticles for antibiotic-resistant bacteria infection. Biomater Sci. 2021 Feb 9;9(3):826-834. 13. Liu R, Zhao L, Cheng X, Han H, Li C, Li D, Liu A, Gao G, Zhou F, Liu F, Jiang Y, Zhu C, Xia Y. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int. 2021 Apr;41(4):720-730. 14. Han H, Xu Z, Cheng X, Zhong Y, Yuan L, Wang F, Li Y, Liu F, Jiang Y, Zhu C, Xia Y. Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19 Patients. mSphere. 2020 Oct 7;5(5):e00922-20. 15.Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, Ye P, Chen X, Wang B, Xu Z, Zhang Q, Xu X, Gao H, Wu X, Li D, Jiang W, Qu J, Xiang C, Li L. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020 Oct;14(5):664-673. 16. Dai K, Huang Y, Chen Z, Sun X, Yang L, Jiang Y. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model. Eur J Immunol. 2018 Apr;48(4):683-695. 17. Jiang WL, Hu XP, Hu ZP, Tang Z, Wu HB, Chen LH, Wang ZW, Jiang YA. Morbidity and Mortality of Nosocomial Infection after Cardiovascular Surgery: A Report of 1606 Cases. Curr Med Sci. 2018 Apr;38(2):329-335. 18. Dai K, Huang L, Huang YB, Chen ZB, Yang LH, Jiang YA. 1810011o10 Rik Inhibits the Antitumor Effect of Intratumoral CD8+ T Cells through Suppression of Notch2 Pathway in a Murine Hepatocellular Carcinoma Model. Front Immunol. 2017 Mar 22;8:320. 19. Dai Kai, Bao Anyu, Ye Peng, Xu Ming, Zhang Qinran, Zhou Yu, Jiang Wanli, Jiang Wubian, Wang Huimin, Zhu Mengfei, Tang lingling, Zhu Chengliang, Xia Yuchen, Jiang Yingan, Zou Xiufen, Li Lanjuan1. Analysis of the risk factors of the prognosis for the mortality of 107 severe patients with COVID-19 in Wuhan. Chinese Journal of Clinical Infectious Diseases, 2020, 13(04): 257-263. 20. Jiang Wanli, Wang Huimin, Ye Peng, Zhang Qinran, Zhou Yu, Jiang Wubian, Chu Aichun, Dai Kai, Hu Xue, Jiang Ying’an, Zou Xiufen. Clinical analysis of 80 death cases with corona virus disease 2019. Chinese Journal of Infectious Diseases, 2021, 39(01): 9-14.